Trials / Completed
CompletedNCT00059735
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.
Detailed description
Renal Cell Carcinoma (RCC) accounts for approximately 2% of all cancers and its incidence is increasing with worldwide deaths of over 100,000 patients per year. About 50% of RCC patients have inoperable or metastatic disease that surgery cannot be performed on. RCC is also considered to be resistant to both radiotherapy and cytotoxic chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of E7070 by assessing progression free survival, tumor response rate, duration of response/stable disease, and survival time. E7070 will be administered as a single iv infusion over 60 minutes on Day 1 of each cycle. Patients will continue treatment with E7070 until they no longer have clinical benefit and have disease progression, or toxicity leads to patient withdrawal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7070 |
Timeline
- Start date
- 2002-05-01
- Completion
- 2003-12-01
- First posted
- 2003-05-07
- Last updated
- 2008-03-05
Locations
5 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT00059735. Inclusion in this directory is not an endorsement.